EN DE
Watch Sugentech Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sugentech Inc (253840) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Sugentech Inc stock KRW 2,223, price KRW 3,815, that is 41.7% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7253840003

SI Sugentech Inc logo Thin data Nov 9, 2026

Sugentech Inc

253840 · KQ
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Low debt
Quality 43/100
Fair value 2,223 KRW · Strongly overvalued
Weak Growth (revenue 5y −25.6 %/yr in KRW)
Negative free cash flow
Trails peers (1/9)
Narrow moat 9/100
Thin data
Watch Sugentech Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

27,044 KRW 3,620 KRW Fair Value 2,223 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 3,620 KRW – 27,044 KRW · fair‑value band 1,467 KRW – 2,779 KRW · the 3,815 KRW price screens above the 2,223 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Sugentech in your weekly email

Every Wednesday you see whether Sugentech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests.

Show moreShow less

It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products.

The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.

Stock analysis

Sugentech Inc (253840) currently trades at 3,815 KRW, while our model-based Fair Value estimate is 2,223 KRW, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: 1,467 KRW (bear) to 2,779 KRW (bull), the price of 3,815 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Sugentech Inc reported revenue of 9.4B KRW in FY2025 versus 77.2B KRW in FY2021, a compound −40.9%/yr. Reported net income was −23.3B KRW in FY2025.

Key figures

Market cap 59.0B KRW (≈ $43.7M) Micro · P/S ratio 6.46 · EPS (TTM) −1,505 KRW · Return on equity −29.1% · Return on assets (EBIT) −4.8% (5-year average) · Operating margin −137% · Revenue (TTM) 9.8B KRW · Revenue growth (YoY) −2.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 50% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −42%, 253840 screens richer than that median.

Fair Value models

Bear 1,467 KRW Fair Value 2,223 KRW Bull 2,779 KRW
Price 3,815 KRW · Downside -41.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 1,467 KRW 2,223 KRW 2,779 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,467 KRW 2,223 KRW 2,779 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 30
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 76
Debt, balance sheet and risk of trouble
Investment 96
Does it invest with discipline instead of growing at any price?
Low Volatility 47
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−54.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
71.5% (2020) → −199.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

253840 screens overvalued: fair value 42% below the price. Compare with Abbott Laboratories, →

Compare Sugentech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −41.7% · Below median
Profitability
Return on assets −23.7% · Bottom 25%
Operating margin (12 months) −137.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −2.8% · Bottom 25%
Balance sheet
Debt / equity 0.14× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.77× · Cheapest 25%
P/S (12 months) 6.04× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 17
HEALTH (low debt)93 · sector 98
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs 253840
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs 253840
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs 253840
DexCom, Inc DXCM $79.41 $87.35 +10% vs 253840
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs 253840
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs 253840
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs 253840
Abbott Laboratories, ABT $109.93 $75.28 −32% vs 253840
Medtronic plc MDT $101.80 $65.61 −36% vs 253840
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs 253840

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sugentech Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sugentech Inc Fair Value". https://www.fairvalue-calculator.com/stock/253840

Frequently asked questions

Is Sugentech Inc (253840) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2,223 KRW versus a price of 3,815 KRW, about 42% lower (overvalued).
What is the fair value of 253840?
Our model-based fair value for Sugentech Inc is 2,223 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 3,815 KRW.
What is the quality score of 253840?
Sugentech Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sugentech Inc (253840)?
Our model-based price target is the fair value of 2,223 KRW (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 1,467 KRW, optimistic scenario 2,779 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Sugentech Inc stock forecast for 2026?
Our models put fair value at 2,223 KRW, about 42% lower versus a price of 3,815 KRW (overvalued). Cautious scenario 1,467 KRW, optimistic scenario 2,779 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Sugentech Inc (253840)?
Sugentech Inc reported trailing-twelve-month revenue of about 9.8B KRW (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Sugentech Inc (253840)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sugentech Inc it is 2,223 KRW per share (as of Nov 9, 2026), against a price of 3,815 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Sugentech Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 253840 trades above its calculated fair value: price 3,815 KRW, fair value 2,223 KRW, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 253840?
No. The price is what the market pays today (3,815 KRW); the fair value is what the company's own numbers justify (2,223 KRW). For Sugentech Inc the two are 1,592 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Sugentech Inc worth?
The market values Sugentech Inc at about 59.0B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 3,815 KRW; our models calculate a fair value of 2,223 KRW per share.
What do the bullish and bearish scenarios say about 253840?
Our models span a range for Sugentech Inc: cautious scenario 1,467 KRW, base 2,223 KRW, optimistic 2,779 KRW per share (as of Nov 9, 2026, price 3,815 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sugentech Inc (253840)?
Balance-sheet figures for Sugentech Inc (as of Nov 9, 2026): return on equity −29.1%, debt of 0.14 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 253840 from its 52-week high?
Sugentech Inc trades at 3,815 KRW, about 50% below its 52-week high of 7,700 KRW and 5% above the low of 3,620 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2,223 KRW is for.
Which stocks are comparable to Sugentech Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sugentech Inc stock attractive at the current price?
The data as of Nov 9, 2026: price 3,815 KRW, calculated fair value 2,223 KRW (−42%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 253840 calculated?
We run Sugentech Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 2,223 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sugentech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sugentech Inc (253840)?
The closing price on Nov 6, 2026 was 3,815 KRW. Our model-based fair value is 2,223 KRW, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sugentech Inc right now?
The price sits above even our optimistic bull case (2,779 KRW). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,467 KRW to 2,779 KRW) leaves room in how you read the outcome.

Key figures of Sugentech Inc

How large is the market capitalisation of Sugentech Inc (253840)?
The market capitalisation of Sugentech Inc is 59.0B KRW (≈ $43.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sugentech Inc (253840)?
The price-to-sales ratio of Sugentech Inc is 6.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sugentech Inc (253840)?
Earnings per share at Sugentech Inc are −1,505 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sugentech Inc (253840)?
The return on equity (ROE) of Sugentech Inc is −29.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sugentech Inc (253840)?
On an EBIT basis the return on assets of Sugentech Inc is −4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sugentech Inc (253840)?
The operating margin of Sugentech Inc is −137% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sugentech Inc (253840)?
Revenue at Sugentech Inc is growing −2.8% versus a year earlier (3y avg −54.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sugentech Inc (253840)?
Earnings per share at Sugentech Inc are growing −84.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sugentech Inc (253840) generate?
The free cash flow of Sugentech Inc is −15.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sugentech Inc (253840) carry?
The net debt of Sugentech Inc is 6.0B KRW (fiscal year 2019). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sugentech Inc in the live analysis

One click puts Sugentech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.